
Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.
Case: A 68-Year-Old Male with Mantle Cell Lymphoma
Initial presentation
Clinical workup
Treatment






